Table 1.
Sociodemographic and clinical data and health behaviors of omeprazole users and non-users followed up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016–2017 (n = 199).
Table 2.
Relative frequency of CKD evolution per stage of users and non-users of omeprazole followed-up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016–2017 (n = 199).
Table 3.
Multivariate analysis using Cox regression for association between evolution of chronic kidney disease and omeprazole and ARBs use in patients followed-up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016–2017 (n = 199).
Fig 1.
Kaplan-Meier estimates for CKD progression among omeprazole users and non-users.
Fig 1 shows the Kaplan-Meier survival plot for the occurrence of CKD evolution to worse stages in omeprazole users and non-users. The follow-up time is shown in the X axis and the cumulative risk of CKD evolution in the Y axis.